Photobiomodulation therapy in the treatment of genitourinary syndrome in postmenopausal women - a placebo-controlled double-blind clinical trial
Abstract
Postmenopausal genitourinary syndrome of menopause (GSM) includes a range of genital, urinary and sexual symptoms caused by estrogen deficiency. As women spend about one-third of their lives postmenopause, effective, non-invasive treatments are needed. This study evaluated the clinical effects of photobiomodulation (PBM) therapy in postmenopausal women with urinary incontinence. A randomized, double-blind, placebo-controlled clinical trial was conducted with women over 50 years of age presenting one or more GSM symptoms. Participants were assigned to receive either PBM or placebo. The PBM group underwent four weekly sessions of 808 nm laser applied to eight vaginal points (4J per point, 40s each). The placebo group followed the same protocol with the device turned off. Results showed a significant reduction in urinary loss in the PBM group, with improved scores on the International Consultation on Incontinence Questionnaire - Short Form. While pelvic pressure and sexual function did not differ significantly, improvements in vaginal dryness and burning were reported. PBM appears to be a promising, non-invasive option for reducing urinary incontinence and enhancing aspects of vaginal health in postmenopausal women. Further studies are needed to confirm long-term effects and optimize treatment protocols.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.